BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 2674333)

  • 1. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
    McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
    J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.
    de Wit R; Tesselaar M; Kok TC; Seynaeve C; Rodenburg CJ; Verweij J; Helle PA; Stoter G
    Eur J Cancer; 1991; 27(11):1383-5. PubMed ID: 1835851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of carboplatin or iproplatin in cervical cancer.
    Lira-Puerto V; Silva A; Morris M; Martinez R; Groshen S; Morales-Canfield F; Tenorio F; Muggia F
    Cancer Chemother Pharmacol; 1991; 28(5):391-6. PubMed ID: 1914084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
    Arseneau J; Blessing JA; Stehman FB; McGehee R
    Invest New Drugs; 1986; 4(2):187-91. PubMed ID: 3525449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.
    Vermorken JB; Gundersen S; Clavel M; Smyth JF; Dodion P; Renard J; Kaye SB
    Ann Oncol; 1993 Apr; 4(4):303-6. PubMed ID: 8518220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).
    van Glabbeke M; Renard J; Pinedo HM; Cavalli F; Vermorken J; Sessa C; Abele R; Clavel M; Monfardini S
    Eur J Cancer Clin Oncol; 1988 Feb; 24(2):255-62. PubMed ID: 3281842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
    Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
    Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.
    Friedman HS; Krischer JP; Burger P; Oakes WJ; Hockenberger B; Weiner MD; Falletta JM; Norris D; Ragab AH; Mahoney DH
    J Clin Oncol; 1992 Feb; 10(2):249-56. PubMed ID: 1732426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
    McGuire WP; Blessing JA; Hatch K; DiSaia PJ
    Invest New Drugs; 1986; 4(2):181-6. PubMed ID: 3733378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of iproplatin in advanced ovarian carcinoma.
    Sessa C; Vermorken J; Renard J; Kaye S; Smith D; ten Bokkel Huinink W; Cavalli F; Pinedo H
    J Clin Oncol; 1988 Jan; 6(1):98-105. PubMed ID: 3335895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II study of carboplatin in cervical carcinoma].
    Noda K; Kato T; Ikeda M; Akiya K; Yajima A; Ueda G; Nishiya I; Takamizawa H; Terashima Y; Tsutsui F
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3067-72. PubMed ID: 3056277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
    Eisenberger M; Hornedo J; Silva H; Donehower R; Spaulding M; Van Echo D
    J Clin Oncol; 1986 Oct; 4(10):1506-9. PubMed ID: 3531424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
    Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Yordan E; Beecham J
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus.
    Sternberg C; Kelsen D; Dukeman M; Leichman L; Heelan R
    Cancer Treat Rep; 1985 Nov; 69(11):1305-7. PubMed ID: 3912041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
    Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
    Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
    Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
    Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.